The durability of external beam radiation therapy for prostate cancer: Can it be identified?

Journal of Urology

Volumn 162, Issue 3 I, 1999, Pages 758-761

  Davis, John W ^a   Kolm, Paul ^a   Wright Jr , George L ^a   Kuban, Deborah ^a   El Mahdi, Anas ^a   Schellhammer, Paul F ^a  

^a Sentara Cancer Resource Centers   (United States)

Author keywords

Follow up studies; Local; Neoplasm recurrence; Prostate specific antigen; Prostatic neoplasms; Radiotherapy

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; BEAM THERAPY; CANCER RECURRENCE; CONTROLLED STUDY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; PRIORITY JOURNAL; PROSTATE CANCER; RISK ASSESSMENT; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 0032835927     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005392-199909010-00036     Document Type: Article

References (21)

1. Goluboff, E. T. and Benson, M. C.: External beam radiation therapy does not offer long-term control of prostate cancer. Urol. Clin. N. Amer., 23: 617, 1996.
2. Zietman, A. L., Coen, J. J., Dallow, K. C. and Shipley, W. U.: The treatment of prostate cancer by conventional radiation therapy: an analysis of long-term outcome. Int. J. Rad. Oncol. Biol. Phys., 32: 287, 1995.
3. Stamey, T. A., Ferrari, M. K. and Schmid, H.-P.: The value of serial prostate specific antigen determinations 5 years after radiotherapy: steeply increasing values characterize 80% of patients. J. Urol., 150: 1856, 1993.
4. Hartford, A. C. and Zietman, A. L.: Prostate cancer: who is best benefited by external beam radiation therapy? Hematol. Oncol. Clin. N. Amer., 10: 595, 1996.
5. Freedman, G. M., Hanlon, A. L., Lee, W. R. and Hanks, G. E.: Young patients with prostate cancer have an outcome justifying their treatment with external beam radiation. Int. J. Rad. Oncol. Biol. Phys., 35: 243, 1996.
6. Zietman, A. L.: Radiation therapy or prostatectomy: an old conflict revisited in the PSA era. a radiation oncologist's viewpoint. Sem. Rad. Oncol., 8: 81, 1998.
7. Kuban, D. A., el-Mahdi, A. M. and Schellhammer, P. F.: The significance of postirradiation prostate biopsy with long-term follow-up. Int. J. Rad. Oncol. Biol. Phys., 24: 409, 1992.
8. Schellhammer, P. F., el-Mahdi, A. M., Wright, G. L., Jr., Kolm, P. and Ragle, R.: Prostate-specific antigen to determine progression-free survival after radiation therapy for localized carcinoma of prostate. Urology, 42: 13, 1993.
9. Zagars, G. K.: Prostate specific antigen as an outcome variable for T1 and T2 prostate cancer treated by radiation therapy. J. Urol., 152: 1786, 1994.
10. Kuban, D. A., el-Mahdi, A. M. and Schellhammer, P. F.: Prostatespecific antigen for pretreatment prediction and posttreatment evaluation of outcome after definitive irradiation for prostate cancer. Int. J. Rad. Oncol. Biol. Phys., 32: 307, 1995.
11. Schellhammer, P. F., el-Mahdi, A. M., Kuban, D. A. and Wright, G. L., Jr.: Prostate-specific antigen after radiation therapy. Prognosis by pretreatment level and post-treatment nadir. Urol. Clin. N. Amer., 24: 407, 1997.
12. Critz, F. A., Levinson, A. K., Williams, W. H., Holladay, D. A. and Holladay, C. T.: The PSA nadir that indicates potential cure after radiotherapy for prostate cancer. Urology, 49: 322, 1997.
13. Critz, F. A., Levinson, K., Williams, W. H., Holladay, D., Holladay, C. and Griffin, V.: Prostate-specific antigen nadir of 0.5 ng/mL or less defines disease freedom for surgically staged men irradiated for prostate cancer. Urology, 49: 668, 1997.
14. American Society for Therapeutic Radiology and Oncology Consensus Panel.: Consensus statement: guidelines for PSA following radiation therapy. Int. J. Rad. Oncol. Biol. Phys., 37: 1035, 1997.
15. Kaplan, E.: Nonparametric estimation from incomplete observations. J. Amer. Stat. Assn., 53: 457, 1958.
16. Flemming, T. R. and Harrington, D. P.: A class of hypothesis test for one and two sample censored survival data. Comm. Stat., A10: 763, 1981.
17. Blasko, J. C. and Cavanagh, W.: Results of brachytherapy: Seattle experience. Monogr. Urol., 18: 125, 1997.
18. Zagars, G. K., Pollack, A., Kavadi, V. S. and von Eschenbach, A. C.: Prostate-specific antigen and radiation therapy for clinically localized prostate cancer. Int. J. Rad. Oncol. Biol. Phys., 32: 293, 1995.
19. Dillioglugil, O., Leibman, B. D., Kattan, M. W., Seale-Hawkins, C., Wheeler, T. M. and Scardino, P. T.: Hazard rates for progression after radical prostatectomy for clinically localized prostate cancer. Urology, 50: 93, 1997.
20. Kadavi, V. S, Zagars, G. K. and Pollack, A.: Serum prostatespecific antigen after radiation therapy for clinically localized prostate cancer: prognostic implications. Int. J. Rad. Oncol. Biol. Phys., 30: 279, 1994.
21. Pollack, A. and Zagars, G. K.: External beam radiotherapy for stage T1/T2 prostate cancer: how does it stack up? Urology, 51: 258, 1998.